Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
Zentalis Pharmaceuticals announced an underwritten public offering of 23 million shares at $3.50 each, expected to raise approximately $80.5 million before expenses. The proceeds will support ongoing clinical trials, preclinical studies, regulatory activities, manufacturing, and other corporate purposes primarily related to their investigational WE…